ANIK (Anika Therapeutics) Total Equity: $133.9 Mil (As of Mar. 2026)


ANIK Anika Therapeutics Inc ANIK
64 GF Score
Price $16.30
GF Value $20.58
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Anika Therapeutics Total Equity?

Anika Therapeutics ANIK +2.96% 64 Total Equity is $133.9 Mil as of Mar. 2026. GuruFocus rates ANIK with a GF Score™ of 64/100 and a GF Value™ of $20.58 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Anika Therapeutics's total equity for the quarter that ended in Mar. 2026 was $133.9 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Anika Therapeutics Total Equity Historical Data

* Premium members only.

The historical data trend for Anika Therapeutics's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anika Therapeutics Total Equity Chart

Anika Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 287.09 285.56 212.27 153.99 143.47

Anika Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 148.40 147.67 146.81 143.47 133.90
ANIK
64GF Score
Anika Therapeutics Inc ANIK
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Anika Therapeutics Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Anika Therapeutics's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=190.27-46.805
=143.5

Anika Therapeutics's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=179.387-45.486
=133.9

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of $133.9 Mil mean?
Anika Therapeutics (ANIK) has a Total Equity of $133.9 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Anika Therapeutics and its competitors.
Is Anika Therapeutics' Total Equity too high?
Anika Therapeutics' current Total Equity is $133.9 Mil. Overall, Anika Therapeutics has a GF Score™ of 64/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Anika Therapeutics' Total Equity compare to LFCR and DERM?
Anika Therapeutics' Total Equity of $133.9 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Drug Manufacturers company?
A good Total Equity depends on the Drug Manufacturers industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Anika Therapeutics and its competitors. Anika Therapeutics's current Total Equity is $133.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anika Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Anika Therapeutics (ANIK) is currently considered Modestly Undervalued. The stock's GF Value™ is $20.58, compared to a current price of $16.30 — trading 20.8% below its estimated fair value. The current Total Equity is $133.9 Mil. Anika Therapeutics' overall GF Score™ is 64/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Anika Therapeutics (ANIK), the current Total Equity is $133.9 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Anika Therapeutics (ANIK) Overvalued in 2026?

Based on GuruFocus' analysis, Anika Therapeutics stock appears to be undervalued. The current stock price of $16.30 is trading 20.8% below its estimated GF Value™ of $20.58. GuruFocus considers Anika Therapeutics to be Modestly Undervalued.

Key valuation signals for ANIK:

  • Total Equity: $133.9 Mil
  • GF Value™: $20.58 vs. price of $16.30 (20.8% below fair value)
  • GF Score™: 64/100 with 4 warning signs

No single metric tells the full story. See the ANIK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Anika Therapeutics Business Description

Other Exchanges AKP:Germany
Address 32 Wiggins Avenue, Bedford, MA, USA, 01730
Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.
64GF Score

Get the complete analysis for ANIK

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$16.30
Price
$20.58
GF Value